Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

Key Inclusion Criteria: * Ages 4 through 26 years, inclusive * Clinical history of allergy to peanuts or peanut-containing foods * Serum IgE to peanut \>0.35 kU/L (determined by UniCAP within the past 12 months) and/or a SPT to peanut \>3 mm compared to control * Experience dose-limiting symptoms at or before the 100mg dose of peanut protein (measured as 200 mg of peanut flour) on abbreviated screening OFC conducted via PRACTALL guidelines * Use of birth control by females of child-bearing potential Key Exclusion Criteria: * History of Cardiovascular disease * History of frequent or repeated, severe or life-threatening episodes of anaphylactic shock * History of other chronic disease * History of eosinophilic gastrointestinal disease * Severe asthma * Mild or moderate asthma if uncontrolled * Use of omalizumab within the past 6 months or current use of other non-traditional forms of allergen immunotherapy * Use of beta-blockers(oral), angiotensin-converting enzyme (ACE) * Pregnancy, lactation * Having the same place of residence as another study subject * Participation in an interventional clinical trial 30 days prior to randomization